Literature DB >> 22313327

Development and psychometric validation of the Diabetes Therapy-Related QOL (DTR-QOL) questionnaire.

Hitoshi Ishii1.   

Abstract

OBJECTIVE: We developed and evaluated the psychometric properties of the Diabetes Therapy-Related QOL (DTR-QOL) as a disease-specific, self-administered questionnaire to assess the influence of diabetes treatment on patient QOL, regardless of treatment method.
METHODS: This new questionnaire was developed and validated in a standardized manner: Item development, pilot-testing and psychometric validation. A survey was conducted using the provisional version of the questionnaire, and reliability and validity were evaluated with psychometric testing.
RESULTS: The provisional version of the questionnaire was generated with 29 items through literature review and pilot testing. For psychometric assessment, analyses were performed on the responses of 284 adult Japanese patients with diabetes. Factor analysis by the principal factor method with promax rotation revealed 4 factors; "burden on social activities and daily activities" (13 items), "anxiety and dissatisfaction with treatment" (8 items), "hypoglycemia" (4 items), and "satisfaction with treatment" (4 items). For reliability, the intraclass correlation was 0.92, and Cronbach's alpha coefficient was 0.94, indicating adequate test-retest reliability and internal consistency. For known-group validity, there were significant differences in scores for following variables: age, diabetes type, HbA1c, treatment method, glycemic control, hypoglycemia, nocturnal hypoglycemia, concern about weight gain, health status (patient assessment), and degree of communication with physician.
CONCLUSIONS: The DTR-QOL, with good reliability and validity, can assess the influence of diabetes treatment on patient QOL. The DTR-QOL can be used regardless of treatment method that patients receive, and this characteristic enables to detect a difference on patients QOL between treatment methods before and after a switch of treatment. Limitations of this study include representativeness of the patient sample. The relatively small number of patients with type 1 diabetes should be noted. Also, responsiveness of the DTR-QOL has not yet been examined.

Entities:  

Mesh:

Year:  2012        PMID: 22313327     DOI: 10.3111/13696998.2012.665111

Source DB:  PubMed          Journal:  J Med Econ        ISSN: 1369-6998            Impact factor:   2.448


  23 in total

1.  Patient-Reported Outcome Measures in Registry-Based Studies of Type 2 Diabetes Mellitus: a Systematic Review.

Authors:  Yu Ting Chen; Yan Zhi Tan; Mcvin Cheen; Hwee-Lin Wee
Journal:  Curr Diab Rep       Date:  2019-11-20       Impact factor: 4.810

2.  The revalidation of the diabetes treatment-related quality-of-life (DTR-QOL) questionnaire in Japan.

Authors:  Hitoshi Ishii; Hyunchung Ray Kim; Bruce Crawford
Journal:  Diabetol Int       Date:  2018-08-28

3.  Satisfaction of switching to combination therapy with lixisenatide and basal insulin in patients with type 2 diabetes receiving multiple daily insulin injection therapy: A randomized controlled trial.

Authors:  Aika Miya; Akinobu Nakamura; Hideaki Miyoshi; Kyu Yong Cho; So Nagai; Yoshio Kurihara; Shin Aoki; Masataka Taguri; Yasuo Terauchi; Tatsuya Atsumi
Journal:  J Diabetes Investig       Date:  2017-07-10       Impact factor: 4.232

4.  Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study.

Authors:  Hitoshi Ishii; Tetsuji Niiya; Yasuhiro Ono; Naoyuki Inaba; Hideaki Jinnouchi; Hirotaka Watada
Journal:  Diabetol Metab Syndr       Date:  2017-01-07       Impact factor: 3.320

5.  Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes receiving conventional therapy: clinical implication of the importance of exercise habits during treatment with ipragliflozin.

Authors:  Mitsutoshi Kato; Kumiko Sakai; Kyoko Saito; Kensuke Tsutsui; Shigeo Yamashita; Noriko Kato
Journal:  Diabetol Int       Date:  2017-02-08

6.  Development and evaluation of the Japanese version of the Audit of Diabetes-Dependent Quality of Life for patients with diabetes.

Authors:  Ayumi Sugawara Hirose; Kazuya Fujihara; Flaminia Miyamasu; Shigeru Iwakabe; Misa Shimpo; Yoriko Heianza; Chika Horikawa; Yoko Yachi; Hirohito Sone
Journal:  Diabetol Int       Date:  2016-03-10

7.  Efficacy and safety of insulin degludec in Japanese patients with type 1 and type 2 diabetes: 24-week results from the observational study in routine clinical practice.

Authors:  Kazuhiro Kobuke; Masayasu Yoneda; Shuhei Nakanishi; Haruya Ohno; Shusaku Maeda; Genshi Egusa
Journal:  J Diabetes Investig       Date:  2015-06-10       Impact factor: 4.232

8.  Effect of switching basal insulin regimen to degludec on quality of life in Japanese patients with type 1 and type 2 diabetes mellitus.

Authors:  Morihiro Okada; Masae Okada; Jun Nishigami; Naoto Yamaaki; Kenji Furukawa; Kiminori Ohyama; Tsutomu Shimada; Yoshimichi Sai
Journal:  J Pharm Health Care Sci       Date:  2015-09-30

9.  Effect of Trelagliptin on Quality of Life in Patients with Type 2 Diabetes Mellitus: Study Protocol.

Authors:  Hitoshi Ishii; Yuki Suzaki; Yuko Miyata
Journal:  Diabetes Ther       Date:  2017-10-26       Impact factor: 2.945

10.  The Influence of Sitagliptin on Treatment-Related Quality of Life in Patients with Type 2 Diabetes Mellitus Receiving Insulin Treatment: A Prespecified Sub-Analysis.

Authors:  Tomoya Mita; Naoto Katakami; Toshihiko Shiraiwa; Hidenori Yoshii; Masahiko Gosho; Hitoshi Ishii; Iichiro Shimomura; Hirotaka Watada
Journal:  Diabetes Ther       Date:  2017-05-17       Impact factor: 2.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.